Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of. For patients with triple-negative breast cancer, there are now several clinical ...

Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

In breast cancer research, the search for effective treatments is constant. At times, the most promising candidates are not newly developed drugs but existing medications whose potential benefits have ...